SCHEDULE: FMR LLC Discloses 11.5% Stake in VOR Biopharma

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 11.5% of VOR Biopharma Inc.'s common stock as of October 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating beneficial ownership of VOR Biopharma Inc. common stock.
• As of October 31, 2025, FMR LLC and Abigail P. Johnson beneficially own an aggregate of 788,447 shares of VOR Biopharma Inc. common stock.
• This ownership represents 11.5% of the total outstanding common stock of VOR Biopharma Inc.
• FMR LLC holds sole voting power over 788,123 shares and sole dispositive power over 788,447 shares.
• Abigail P. Johnson holds sole dispositive power over 788,447 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Select Biotechnology Portfolio, an entity associated with FMR LLC, holds 784,902 shares, also representing 11.5% of the outstanding common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant passive investment by a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson, in VOR Biopharma Inc. This suggests a positive long-term view on the company's prospects, as the shares were acquired in the ordinary course of business and not for control-influencing purposes. While not a direct endorsement of immediate performance, it reflects confidence from a respected financial entity.

Positives

• Significant institutional investment from FMR LLC, a major asset manager, signals confidence in VOR Biopharma Inc.
• The acquisition of shares in the ordinary course of business suggests a long-term investment perspective rather than an activist stance.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

The disclosure of a significant stake by a major institutional investor like FMR LLC in a biopharma company such as VOR Biopharma Inc. is a common occurrence in the industry. It indicates that large asset managers are actively investing in companies they believe have growth potential, often in sectors like biotechnology which require substantial capital and long-term development cycles.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure required when an entity acquires beneficial ownership exceeding 5% of a company's outstanding shares.
• The percentage of ownership (11.5%) is substantial for an institutional investor, placing FMR LLC among the larger shareholders of VOR Biopharma Inc.
• This level of ownership is comparable to stakes held by other major asset managers (e.g., BlackRock, Vanguard, State Street) in similar-sized biopharma companies, reflecting a typical institutional investment strategy rather than an unusual or activist position.

Corporate Governance

Related Party Transactions

• The filing describes the relationship between FMR LLC, its subsidiaries (FIAM LLC, Fidelity Management & Research Company LLC), and Abigail P. Johnson, clarifying how beneficial ownership is attributed within the FMR group. This is an internal FMR group relationship, not a related party transaction involving VOR Biopharma Inc.

Stakeholder Impact

• Shareholders: Increased confidence due to a significant institutional investor taking a substantial stake, potentially signaling long-term value.
• Management: Validation of the company's strategy and potential, attracting further institutional interest.

Key Dates

Recommendation

The disclosure of a significant 11.5% stake by FMR LLC and Abigail P. Johnson in VOR Biopharma Inc. is a positive signal, indicating institutional confidence in the company's long-term prospects. However, as a Schedule 13G filing, it is a passive ownership disclosure and does not provide new operational or financial performance data. While the institutional backing is reassuring, it doesn't inherently suggest an immediate 'buy' given the lack of new fundamental catalysts. A 'hold' recommendation is appropriate, acknowledging the positive institutional interest while awaiting further operational updates or financial results from VOR Biopharma Inc. to justify a stronger position.

Keywords

VOR Biopharma, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, Investment, Equity Stake